CN1772081A - 一种治疗腹泻病的中药组合物 - Google Patents
一种治疗腹泻病的中药组合物 Download PDFInfo
- Publication number
- CN1772081A CN1772081A CNA2005100868068A CN200510086806A CN1772081A CN 1772081 A CN1772081 A CN 1772081A CN A2005100868068 A CNA2005100868068 A CN A2005100868068A CN 200510086806 A CN200510086806 A CN 200510086806A CN 1772081 A CN1772081 A CN 1772081A
- Authority
- CN
- China
- Prior art keywords
- group
- chinese medicine
- medicine composition
- test
- diarrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 24
- 238000011282 treatment Methods 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 22
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 17
- 230000006837 decompression Effects 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 2
- 206010012742 Diarrhoea infectious Diseases 0.000 abstract description 13
- 208000001848 dysentery Diseases 0.000 abstract description 12
- 230000001154 acute effect Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract 1
- 240000002505 Pogostemon cablin Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000508269 Psidium Species 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 208000004232 Enteritis Diseases 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 230000003908 liver function Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 238000002562 urinalysis Methods 0.000 description 10
- 230000001142 anti-diarrhea Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 241000702670 Rotavirus Species 0.000 description 7
- 238000009534 blood test Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 6
- 208000004429 Bacillary Dysentery Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 201000005113 shigellosis Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 241001295925 Gegenes Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010051511 Viral diarrhoea Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000002416 diarrheagenic effect Effects 0.000 description 3
- 230000000741 diarrhetic effect Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical group C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000011951 anti-virus test Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000010015 huanglian Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 239000009711 Huoxiang-zhengqi Substances 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008838 gegenqinlian Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 炭末在小肠推进率(%) |
空白对照组 | 60.88±2.317 | |
低剂量组 | 1 | 50.95±7.332**△ |
中剂量组 | 2 | 46.95±2.723**△ |
高剂量组 | 4 | 42.48±4.443**△ |
对照组 | 0.25 | 44.84±6.052** |
组别 | 剂量(g/kg) | 炭末在小肠推进率(%) |
空白对照组 | 60.80±5.772 | |
低剂量组 | 1 | 51.90±5.541**△ |
中剂量组 | 2 | 49.51±2.416**▲▲ |
高剂量组 | 4 | 45.68±3.490**▲▲ |
对照组 | 0.25 | 55.38±5.630** |
组别 | 水吸收量(ml) | Cl-吸收量(mg/ml) |
空白对照组 | 0.34±0.117 | 0.64±0.117 |
低剂量组 | 0.53±0.095**△ | 1.01±0.099**▲ |
高剂量组 | 0.62±0.123**△ | 1.14±0.118**△ |
对照组 | 0.66±0.135** | 1.12±0.092** |
组别 | 术 后 | ||||
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | |
空白对照组 | 0 | 577.8±94.1a | 830.0±66.7ab | 792.8±68.4ab | 731.6±57.7ab |
对照组 | 0 | 572.2±53.8a | 101.4±11.3abe | 60.2±2.5abce | 31.4±3.1bce |
低剂量组 | 0 | 588.4±82.8a | 101.6±7.2abc | 58.9±2.7be | 32.3±2.8bce |
中剂量组 | 0 | 592.3±81.4a | 101.2±6.8abe | 58.1±3.2be | 31.8±3.0bce |
高剂量组 | 0 | 608.4±70.1a | 100.5±6.0abe | 57.8±3.1abce | 30.3±1.8bce |
组别 | 术 后 | ||||
第0天 | 第1天 | 第2天 | 第3天 | 第4天 | |
空白对照组 | 0 | 349.1±46.2a | 600.8±21.8ab | 516.8±33.7abc | 202.2±27.8abcd |
对照组 | 0 | 334.6±62.0a | 203.6±39.1abe | 69.6±8.6abce | 5.1±0.9bcde |
低剂量组 | 0 | 302.4±37.2a | 213.4±24.4abe | 47.5±11.1abce | 4.4±0.6bcde |
中剂量组 | 0 | 327.2±56.4a | 186.5±34.2abe | 48.8±9.4abce | 4.7±0.8bcde |
高剂量组 | 0 | 360.4±65.0a | 100.5±41.3abe | 50.4±8.4bce | 5.0±0.8bce |
组别 | 剂量(g/Kg) | 排便百分率% |
空白对照组 | 67.02±3.413 | |
低剂量组 | 1 | 40.29±3.592**△ |
中剂量组 | 2 | 34.32±5.640**△ |
高剂量组 | 4 | 31.99±4.495** |
对照组 | 0.25 | 38.11±4.916** |
组别 | 剂量(g/Kg) | 小鼠平均扭体次数 |
空白对照组 | 11.60±2.171 | |
低剂量组 | 1 | 7.00±1.333**▲ |
高剂量组 | 4 | 6.20±1.032**△ |
对照组 | 0.25 | 6.30±0.949** |
组别 | 平均痛阈值秒 | ||
给药前 | 给药15分钟后 | 给药30分钟后 | |
空白对照组 | 3.40±0.699 | 3.10±0.738 | 3.20±0.632 |
低剂量组 | 3.10±30.739 | 7.10±1.449 | 10.10±1.792 |
高剂量组 | 3.10±0.738 | 7.70±1.567 | 10.70±2.359 |
对照组 | 3.20±0.632 | 7.60±1.349 | 10.60±1.578 |
组别 | 剂量(g/Kg) | 腹腔洗出液光密度(OD) |
空白对照组 | 1.01±0.267 | |
低剂量组 | 1 | 0.68±0.204**△ |
高剂量组 | 4 | 0.63±0.262**△ |
对照组 | 0.25 | 0.67±0.226** |
组别 | 剂量(g/Kg) | 平均肿胀程度(mg) |
空白对照组 | 3.60±1.075 | |
低剂量组 | 1 | 2.50±0.707**△ |
高剂量组 | 4 | 2.20±0.789**△ |
对照组 | 0.25 | 2.45±0.985** |
组别 性别 | N | 0w | 1w | 2w | 3w | 4w | |
对照组 | 雌 | 10 | 171.3±24.2 | 183.5±20.8 | 194.6±48.5 | 206.2±47.6 | 208.3±18.4 |
雄 | 10 | 173.8±25.4 | 206.1±30.7 | 224.5±29.7 | 256.1±34.5 | 207.5±32.1 | |
合计 | 20 | 172.6±26.1 | 194.8±27.6 | 209.5±29.3 | 231.1±38.4 | 239.3±16.7 | |
高剂量 | 雌 | 10 | 167.3±22.5 | 188.5±17.9 | 196.5±16.7 | 215.7±24.8 | 234.8±27.5 |
雄 | 10 | 176.0±18.7 | 187.0±21.3 | 198.2±20.3 | 219.2±18.7 | 138.6±19.4 | |
合计 | 20 | 171.7±25.8 | 187.8±24.6 | 197.4±22.4 | 217.5±25.1 | 236.7±23.7 | |
中剂量 | 雌 | 10 | 169.4±16.8 | 131.6±20.7 | 191.7±19.3 | 208.7±21.8 | 217.4±24.3 |
雄 | 10 | 171.3±15.3 | 192.3±18.5 | 213.2±21.4 | 232.4±22.6 | 245.5±27.6 | |
合计 | 20 | 170.4±17.5 | 186.9±19.7 | 202.5±22.7 | 200.6±24.5 | 231.5±26.7 | |
低剂量 | 雌 | 10 | 166.4±18.4 | 184.3±22.5 | 192.3±22.5 | 207.2±20.6 | 217.2±17.6 |
雄 | 10 | 177.5±20.1 | 199.6±23.1 | 207.6±29.8 | 237.4±32.1 | 253.7±35.7 | |
合计 | 20 | 171.9±22.3 | 192.0±20.5 | 209.0±28.4 | 222.3±34.6 | 235.5±38.4 |
试验中心 | 入组病例数 | 脱落病例数 | 剔除病例数 | ||||||
试验组 | 对照组 | 合计 | 试验组 | 对照组 | 合计 | 试验组 | 对照组 | 合计 | |
中心一 | 132 | 44 | 176 | 0 | 0 | 0 | 1 | 0 | 1 |
中心二 | 66 | 22 | 88 | 1 | 1 | 2 | 4 | 2 | 6 |
中心三 | 66 | 22 | 88 | 0 | 0 | 0 | 0 | 0 | 0 |
中心四 | 66 | 22 | 88 | 0 | 0 | 0 | 0 | 0 | 0 |
中心五 | 66 | 22 | 88 | 0 | 0 | 0 | 0 | 0 | 0 |
合计 | 396 | 132 | 528 | 0 | 0 | 2 | 5 | 2 | 7 |
试验中心 | ITT集 | PP集 | 安全集 | ||||||
试验组 | 对照组 | 合计 | 试验组 | 对照组 | 合计 | 试验组 | 对照组 | 合计 | |
中心一中心二中心三中心四中心五 | 13262666666 | 4420222222 | 17682888888 | 13161666666 | 4419222222 | 17580888888 | 13263666666 | 4421222222 | 17684888888 |
合计 | 392 | 130 | 522 | 390 | 129 | 519 | 393 | 131 | 524 |
数据集 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
ITTPP | 有效无效合计 | 340(86.73)52(13.27)392(100.00) | 107(82.31)23(17.69)130(100.00) | 44775522 | 1.5521 | 0.2128 |
有效无效合计 | 338(86.67)52(13.33)390(100.00) | 107(82.95)22(17.05)129(100.00) | 44574519 | 1.0957 | 0.2952 |
数据集 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
ITTPP | 有效无效合计 | 177(91.24)17(8.76)194(100.00) | 52(81.25)12(18.75)64(100.00) | 22929258 | 4.7925 | 0.0286 |
有效无效合计 | 176(91.19)17(8.81)193(100.00) | 52(82.54)11(17.46)63(100.00) | 22828256 | 3.6356 | 0.0566 |
数据集 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
ITTPP | 有效无效合计 | 163(82.32)35(17.68)198(100.00) | 55(83.33)11(16.67)66(100.00) | 21846264 | 0.0350 | 0.8517 |
有效无效合计 | 162(82.23)35(17.77)197(100.00) | 55(83.33)11(16.67)66(100.00) | 21746263 | 3.0413 | 0.8390 |
指标 | 分组 | 例数 | 治疗前 | 治疗后 | 前后差值组内比较 | 前后差值组间比较 | |||
均值±标准差 | 均值±标准差 | 均值±标准差 | t | p | t | p | |||
心率脉搏呼吸收缩压舒张压 | 试验组对照组试验组对照组试验组对照组试验组对照组试验组对照组 | 393131393130393131393131393131 | 77.18±8.8178.65±10.2277.22±8.7978.62±10.1418.63±1.6718.72±1.58118.11±13.10118.08±12.1071.26±6.7171.91±7.69 | 75.36±7.3074.95±7.7275.28±7.1974.95±7.6818.02±1.6817.95±1.78118.28±11.79118.89±11.0071.30±6.2572.29±6.60 | 1.82±6.633.69±8.281.93±6.383.66±8.150.61±1.300.77±1.26-0.17±6.37-0.81±6.16-0.05±4.90-0.38±4.93 | 5.4455.1106.0075.1259.2787.025-0.530-1.504-0.216-0.886 | 0.0000.0000.0000.0000.0000.0000.5960.1350.8290.377 | -2.623-2.489-1.2291.0020.663 | 0.0090.0130.2200.3170.508 |
指标 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
HB | 正常异常合计 | 389(99.23)3(0.77)392(100.00) | 127(97.69)3(2.31)130(100.00) | 5166522 | 2.0401 | 0.1532 |
RBCWBC尿常规大便常规肝功能BUNCr心电图 | 正常异常合计正常异常合计正常异常合计异常合计正常合计正常合计正常合计正常异常合计 | 389(99.23)3(0.77)392(100.00)386(98.72)5(1.28)391(100.00)390(99.49)2(0.51)392(100.00)392(100.00)( )392(100.00)392(100.00)( )392(100.00)392(100.00)( )392(100.00)392(100.00)( )392(100.00)381(98.20)7(1.80)388(100.00) | 128(98.46)2(1.54)130(100.00)127(97.69)3(2.31)130(100.00)127(97.69)3(2.31)130(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)129(99.23)1(0.77)130(100.00) | 5175522513852151755225225225225225225225225225108518 | 0.61400.68183.31850.6845 | 0.43330.40900.06850.4080 |
指标 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
HB | 正常异常合计 | 391(99.49)2(0.51)393(100.00) | 128(98.46)2(1.54)130(100.00) | 5194523 | 1.3617 | 0.2432 |
RBCWBC尿常规大便常规肝功能BUNCr心电图 | 正常异常合计正常异常合计正常合计正常异常合计正常合计正常合计正常合计正常异常合计 | 391(99.49)2(0.51)393(100.00)388(98.73)5(1.27)393(100.00)( )393(100.00)393(100.00)366(93.13)27(6.87)393(100.00)( )392(100.00)392(100.00)392(100.00)( )392(100.00)392(100.00)( )392(100.00)384(98.46)6(1.54)390(100.00) | 128(98.46)2(1.54)130(100.00)129(99.23)1(0.77)130(100.00)( )129(100.00)129(100.00)119(90.84)12(9.16)131(100.00)( )130(100.00)130(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)131(100.00)0(0.00)131(100.00) | 51945235176523522522485395245225225225225225225156521 | 1.36170.21750.74662.0350 | 0.24320.64090.38760.1537 |
指标 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
HB | -/+-/+合计 | 388(99.74)1(0.26)389(100.00) | 127(100.00)0(0.00)127(100.00) | 5151516 | 0.3265 | 0.5677 |
RBCWBC尿常规肝功能BUNCr心电图 | +/-+/+合计-/--/+合计+/-+/+合计-/--/+合计+/-+/+合计-/-合计+/-合计-/-合计-/-合计-/-合计-/--/+合计+/-+/+合计 | 2(66.67)1(33.33)3(100.00)388(99.74)1(0.26)389(100.00)2(66.67)1(33.33)3(100.00)384(99.48)2(0.52)386(100.00)2(40.00)3(60.00)5(100.00)391(100.00)( )391(100.00)2(100.00)2(100.00)391(100.00)( )391(100.00)391(100.00)( )391(100.00)391(100.00)( )391(100.00)376(99.47)2(0.53)378(100.00)4(50.00)4(50.00)8(100.00) | 1(33.33)2(66.67)3(100.00)128(100.00)0(0.00)128(100.00)0(0.00)2(100.00)2(100.00)126(100.00)0(0.00)126(100.00)3(75.00)1(25.00)4(100.00)126(100.00)( )126(100.00)3(100.00)3(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)130(100.00)( )130(100.00)130(100.00)0(0.00)130(100.00)1(100.00)0(0.00)1(100.00) | 33651615172355102512549517517555215215215215215215062508549 | 0.55560.32901.77780.65410.98000.68920.8000 | 0.45610.56620.18240.41860.32220.40640.3711 |
试验中心 | 药物编号 | 分组 | 不良事件名称 | 开始时间 | 结束时间 | 转归 | 特点 | 严重程度 | 措施 | 与试验药物的关系 | 纠正治疗 | 患者是否退出 |
中心二 | 216 | 对照组 | 恶心 | 第2天 | 第3天 | 消失 | 阵发性 | 轻 | 药物暂停后又恢复 | 可能有关 | 否 | 否 |
中心二 | 221 | 试验组 | 恶心 | 第1天 | 第2天 | 消失 | 阵发性1次 | 轻 | 继续用药 | 可能有关 | 否 | 否 |
中心二 | 236 | 试验组 | 左踝扭伤 | 第2天 | 治疗结束仍存在 | 继续 | 持续性 | 轻 | 继续用药 | 无关 | 否 | 否 |
中心四 | 365 | 试验组 | 头痛 | 第2天 | 半天 | 消失 | 持续性12小时 | 轻 | 继续用药 | 可能有关 | 否 | 否 |
中心四 | 437 | 对照组 | 头晕 | 10小时 | 1天 | 消失 | 阵发性发作7次 | 轻 | 继续用药 | 可能有关 | 否 | 否 |
指标 | 分类 | 试验组 | 对照组 | 合计 | X2值 | P值 |
不良反应 | 无有合计 | 390(99.24)3(0.76)393(100.00) | 129(98.47)2(1.53)131(100.00) | 5195524 | 0.605 | 0.603 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100868068A CN100358549C (zh) | 2005-11-07 | 2005-11-07 | 一种治疗腹泻病的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100868068A CN100358549C (zh) | 2005-11-07 | 2005-11-07 | 一种治疗腹泻病的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1772081A true CN1772081A (zh) | 2006-05-17 |
CN100358549C CN100358549C (zh) | 2008-01-02 |
Family
ID=36759332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100868068A Active CN100358549C (zh) | 2005-11-07 | 2005-11-07 | 一种治疗腹泻病的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100358549C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101642552B (zh) * | 2009-05-31 | 2011-12-14 | 李跃 | 用于治疗慢性腹泻的膏药 |
CN101564528B (zh) * | 2009-06-05 | 2012-01-04 | 刘百祥 | 用于治疗腹泻病的中药及其制备方法 |
CN104435327A (zh) * | 2014-11-11 | 2015-03-25 | 成都果睿医药科技有限公司 | 含有黄连的用于治疗腹泻的药物组合物 |
CN104706784A (zh) * | 2015-03-25 | 2015-06-17 | 唐肖近 | 一种治疗腹泻的中药 |
CN104997993A (zh) * | 2015-07-09 | 2015-10-28 | 张鑫 | 一种治疗结肠感染性腹泻的中药制剂 |
CN105486760A (zh) * | 2014-09-19 | 2016-04-13 | 惠州市九惠制药股份有限公司 | 一种小儿连番止泻颗粒的质量检测方法 |
CN105477094A (zh) * | 2014-09-19 | 2016-04-13 | 惠州市九惠制药股份有限公司 | 一种治疗小儿腹泻中药颗粒剂的制备方法 |
CN108392502A (zh) * | 2018-05-24 | 2018-08-14 | 广西壮族自治区药用植物园 | 治疗腹泻的瑶药复方番石榴叶合剂及其制备方法 |
CN111494477A (zh) * | 2020-05-28 | 2020-08-07 | 惠州市九惠制药股份有限公司 | 一种连番止泻微丸包衣颗粒及其制备方法 |
CN112516205A (zh) * | 2020-12-29 | 2021-03-19 | 惠州市九惠制药股份有限公司 | 一种治疗幽门螺杆菌感染的中药组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1050762C (zh) * | 1997-05-24 | 2000-03-29 | 金文媺 | 三花泻停液 |
CN1471933A (zh) * | 2002-07-29 | 2004-02-04 | 张银上 | 结肠炎康复胶囊 |
-
2005
- 2005-11-07 CN CNB2005100868068A patent/CN100358549C/zh active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101642552B (zh) * | 2009-05-31 | 2011-12-14 | 李跃 | 用于治疗慢性腹泻的膏药 |
CN101564528B (zh) * | 2009-06-05 | 2012-01-04 | 刘百祥 | 用于治疗腹泻病的中药及其制备方法 |
CN105486760A (zh) * | 2014-09-19 | 2016-04-13 | 惠州市九惠制药股份有限公司 | 一种小儿连番止泻颗粒的质量检测方法 |
CN105477094A (zh) * | 2014-09-19 | 2016-04-13 | 惠州市九惠制药股份有限公司 | 一种治疗小儿腹泻中药颗粒剂的制备方法 |
CN104435327A (zh) * | 2014-11-11 | 2015-03-25 | 成都果睿医药科技有限公司 | 含有黄连的用于治疗腹泻的药物组合物 |
CN104706784A (zh) * | 2015-03-25 | 2015-06-17 | 唐肖近 | 一种治疗腹泻的中药 |
CN104997993A (zh) * | 2015-07-09 | 2015-10-28 | 张鑫 | 一种治疗结肠感染性腹泻的中药制剂 |
CN108392502A (zh) * | 2018-05-24 | 2018-08-14 | 广西壮族自治区药用植物园 | 治疗腹泻的瑶药复方番石榴叶合剂及其制备方法 |
CN111494477A (zh) * | 2020-05-28 | 2020-08-07 | 惠州市九惠制药股份有限公司 | 一种连番止泻微丸包衣颗粒及其制备方法 |
CN112516205A (zh) * | 2020-12-29 | 2021-03-19 | 惠州市九惠制药股份有限公司 | 一种治疗幽门螺杆菌感染的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100358549C (zh) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1772081A (zh) | 一种治疗腹泻病的中药组合物 | |
CN109674958A (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN101244193A (zh) | 一种治疗呼吸道疾病的中药及其制备方法 | |
CN1772079A (zh) | 一种治疗上呼吸道感染的药物及其制备方法 | |
CN104127749A (zh) | 一种治疗有机磷农药中毒的中药及制备方法 | |
CN102895326B (zh) | 一种治疗小儿感冒的中药组合物及其制备方法 | |
CN1403138A (zh) | 一种治疗泌尿系统感染和前列腺炎的中药复方制剂及制备 | |
CN1813819A (zh) | 猴头子实体或猴头菌丝体及培养物提取物及制剂和制法 | |
CN1304735A (zh) | 一种治疗慢性结肠炎的药物 | |
CN1738633A (zh) | 来自药用植物的抗肥胖组分及其组合物 | |
CN1323668C (zh) | 一种药物组合物及其制药用途 | |
CN1686271A (zh) | 一种药物组合物 | |
CN116139237A (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN101049345A (zh) | 一种治疗口腔和咽喉疾病的制剂及其制备方法 | |
CN100337658C (zh) | 治疗感冒风热症的中药组合物及其制备方法 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
CN1526440A (zh) | 治疗肌肉萎缩肌无力-痿症的中药复方制剂及制备方法 | |
CN1237983C (zh) | 复方贯众阿司匹林制剂 | |
CN1679693A (zh) | 一种治疗肝病的药物及其制备方法 | |
CN1209162C (zh) | 治疗痤疮、黄褐斑的药物组合物 | |
CN103446410B (zh) | 一种治疗病毒性心肌炎的中药制剂 | |
CN116036188B (zh) | 防治鸡球虫病的中药组合物及其制备方法与应用 | |
CN1310655C (zh) | 一种疏风感冒口服液及其制备方法 | |
CN107569576B (zh) | 一种中药养肝护肝复方制剂及其制备方法和应用 | |
CN1621058A (zh) | 一种治疗和预防胆道炎症的中药及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUIZHOU JIUHUI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUIZHOU JIUHUI PHARMACEUTICAL FACTORY Effective date: 20070309 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070309 Address after: 516007 Nan'an Road, Guangdong, Huizhou Applicant after: Huizhou-Jiuhui Pharmaceutical Co., Ltd. Address before: 516007 Nan'an Road, Guangdong, Huizhou Applicant before: Huizhou Jiuhui Pharmaceutical Factory |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HUIZHOU CITY JIUHUI PHARMACY CO.,LTD. Free format text: FORMER NAME OR ADDRESS: HUIZHOU JIUHUI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Nan'an Road, Huizhou, Guangdong Patentee after: Huizhou Jiuhui Pharmaceutical Co., Ltd. Address before: Nan'an Road, Huizhou, Guangdong Patentee before: Huizhou-Jiuhui Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210820 Address after: 516000 office building of Henan an Dalang Du Jiuhui Pharmaceutical Co., Ltd., Huizhou City, Guangdong Province Patentee after: Huizhou Jiuhui Pharmaceutical Co.,Ltd. Address before: 516007 Nan'an Road, Guangdong, Huizhou Patentee before: JIUHUI PHARMACEUTICAL Co.,Ltd. |